期刊
GENOME MEDICINE
卷 11, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s13073-019-0652-8
关键词
-
资金
- F. Hoffmann-La Roche/Genentech, a member of the Roche Group
Editorial summaryPersonalized care of cancer patients undergoing treatment with immune checkpoint inhibitors will require approaches that can predict their susceptibility to immune-related adverse events. Understanding the role of germline genetic factors in determining individual responses to immunotherapy will deepen our understanding of immune toxicity and, importantly, it may lead to tools for identifying patients who are at risk.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据